تحلیل ساختاری موانع پذیرش بلاک‌چین در زنجیره تأمین صنعت داروسازی: رویکرد تلفیقی دلفی فازی، مدل‌سازی ساختاری تفسیری و تحلیل میک‌مک

نوع مقاله : پژوهشی

نویسندگان

1 استادیار، گروه مدیریت، واحد نجف آباد، دانشگاه آزاد اسلامی، نجف آباد، ایران

2 دانشجوی دکتری مدیریت بازرگانی، گروه مدیریت، واحد سمنان، دانشگاه آزاد اسلامی، سمنان، ایران

3 کارشناسی ارشد مدیریت کسب و کار، گروه مدیریت، واحد نجف آباد، دانشگاه آزاد اسلامی، نجف اباد، ایران

چکیده

با گسترش رویکردهای دیجیتال در صنعت داروسازی، فناوری بلاک‌چین به‌عنوان ابزاری نوین برای ارتقای شفافیت، قابلیت رهگیری و امنیت داده‌ها در زنجیره تأمین دارویی مورد توجه قرار گرفته است. با وجود این ظرفیت‌ها، پیاده‌سازی مؤثر بلاک‌چین مستلزم تعامل هماهنگ میان n هادهای حاکمیتی، بازیگران زنجیره تأمین و زیرساخت‌های فناورانه است و در عمل با مجموعه‌ای از موانع فنی، سازمانی، مالی و مقرراتی مواجه می‌شود که درک ساختار علّی آن‌ها برای سیاست‌گذاری و تصمیم‌گیری راهبردی ضروری است. هدف این پژوهش، شناسایی و تحلیل ساختاری موانع کلیدی پیاده‌سازی بلاک‌چین در زنجیره تأمین صنعت داروسازی ایران است. در مرحله نخست، با مرور نظام‌مند ادبیات و به‌کارگیری روش دلفی فازی، ده مانع معتبر شناسایی شد. در مرحله دوم، روابط سلسله‌مراتبی و وابستگی‌های علّی این موانع با استفاده از مدل‌سازی ساختاری–تفسیری (ISM) تحلیل گردید و در مرحله سوم، به‌منظور ارزیابی قدرت نفوذ و وابستگی متغیرها، تحلیل میک‌مک (MICMAC) انجام شد. نتایج نشان داد که نبود زیرساخت فنی مناسب و پیچیدگی فناوری بلاک‌چین به‌عنوان عوامل ریشه‌ای و مستقل، بیشترین تأثیر را بر سایر موانع دارند، در حالی‌که نبود حمایت مدیریت ارشد و مقاومت کارکنان در برابر تغییر به‌عنوان عوامل وابسته در سطوح بالاتر ساختار تحلیلی قرار می‌گیرند. بر این اساس، راهکارهایی نظیر توسعه زیرساخت‌های دیجیتال متناسب با الزامات صنعت دارو، ارتقای دانش و مهارت‌های فنی نیروی انسانی، تقویت تعهد مدیریتی و تدوین چارچوب‌ها و استانداردهای ملی بلاک‌چین پیشنهاد می‌شود. این پژوهش با ارائه یک چارچوب تحلیلی ساختاریافته و بومی‌شده، می‌تواند مبنایی کاربردی برای مدیران و سیاست‌گذاران حوزه دارو در مسیر دیجیتال‌سازی پایدار و مبتنی بر بلاک‌چین فراهم آورد.

کلیدواژه‌ها

موضوعات


عنوان مقاله [English]

Structural Analysis of Barriers to Blockchain Adoption in the Pharmaceutical Supply Chain: An Integrated Fuzzy Delphi, Interpretive Structural Modeling, and MICMAC Approach

نویسندگان [English]

  • Masoud Barati 1
  • Reyhaneh Bidram 2
  • parham TalaiePour 3
1 Assistant Professor, Department of management, Na.C., Islamic Azad University, Najafabad, Iran.
2 PhD Student in Business Management, Department of management, Se.C., Islamic Azad University, Semnan, Iran.
3 Master of Business Administration, Department of management, Na.C., Islamic Azad University, Najafabad, Iran.
چکیده [English]

With the expansion of digital approaches in the pharmaceutical industry, blockchain technology has gained increasing attention as an innovative tool for enhancing transparency, traceability, and data security across pharmaceutical supply chains. Despite these potential benefits, effective blockchain implementation requires coordinated interaction among regulatory institutions, supply chain actors, and technological infrastructures, and in practice faces a set of interrelated technical, organizational, financial, and regulatory barriers whose underlying causal structure must be clearly understood. This study aims to identify and structurally analyze the key barriers to blockchain implementation in Iran’s pharmaceutical supply chain. In the first phase, a systematic literature review combined with the Fuzzy Delphi method was employed to identify ten validated barriers. In the second phase, the hierarchical and causal relationships among these barriers were examined using Interpretive Structural Modeling (ISM). In the third phase, MICMAC analysis was applied to assess the driving power and dependence of the identified variables. The findings indicate that inadequate technical infrastructure and technological complexity emerge as root and independent barriers exerting the strongest influence on other obstacles, whereas lack of top management support and employee resistance to change appear as dependent barriers located at higher levels of the structural model. Accordingly, this study proposes strategies such as developing pharmaceutical-specific digital infrastructure, enhancing technical competencies of the workforce, strengthening managerial commitment, and establishing national blockchain standards tailored to the pharmaceutical sector. By presenting a structured and context-specific analytical framework, this research provides practical insights for policymakers and industry decision-makers seeking to advance sustainable, blockchain-based digital transformation in pharmaceutical supply chains.

کلیدواژه‌ها [English]

  • Blockchain
  • Pharmaceutical Supply Chain
  • Interpretive Structural Modeling
  • Fuzzy Delphi
  • MICMAC Analysis

Smiley face

[1] A. Chang, N. El-Rayes, & J. Shi, "Blockchain Technology for Supply Chain Management: A Comprehensive Review," FinTech, vol. 1, no. 2, pp. 191-205, 2022, doi: 10.3390/fintech1020015.
[2] R. Cole, M. Stevenson, and J. Aitken, "Blockchain technology: implications for operations and supply chain management," Supply Chain Management: An International Journal, vol. 24, no. 4, pp. 469–483, 2019.
[3] S. Saberi, M. Kouhizadeh, and M. Nair, "Blockchain technology in supply chain management: Applications, opportunities and challenges," International Journal of Production, vol. 231, p. 107546, 2019.
[4] J.-H. Tseng, Y.-C. Liao, B. Chong, and S.-w. Liao, "Governance on the Drug Supply Chain via Gcoin Blockchain," International Journal of Environmental Research and Public Health, vol. 15, no. 6, p. 1055, 2018. https://doi.org/10.3390/ijerph15061055
[5] K. Kutybayeva, A. Razaque, and H. M. Rai, "Enhancing Pharmaceutical Supply Chain Transparency and Security with Blockchain and Big Data Integration," Procedia Computer Science, vol. 259, pp. 1511-1522, 2025. https://doi.org/10.1016/j.procs.2025.04.106
[6] M. Rafieian Esfahani, B. Yazdani, M. Barati, A. Naqsh, and N. Janatian, "Designing a supply chain sustainability maturity model with a continuous improvement approach (Case study: Iranian pharmaceutical industry)," Supply Chain Management, vol. 25, no. 81, pp. 43-66, 2023. (In Persian)
[7] B. Anthony Jnr, "Investigating the decentralized governance of distributed ledger infrastructure implementation in extended enterprises," Journal of the Knowledge Economy, vol. 14, no. 4, pp. 5003–5032, 2023.
[8] A. Wieland, "Dancing the supply chain: Toward transformative supply chain management," Journal of Supply Chain Management, vol. 57, no. 1, pp. 58–73, 2021.
[9] L. Montag, "Circular economy and supply chains: Definitions, conceptualizations, and research agenda of the circular supply chain framework," Circular Economy and
Sustainability, vol. 3, no. 1, pp. 35–75, 2023, doi: 10.1007/s43615-022-00172-y.
[10] M. S. Brandao and M. Godinho Filho, "Changing terms, evolving strategies: the tailoring of supply chain management terms and its implications," Supply Chain Management: An International Journal, vol. 29, no. 4, pp. 778–793, 2024.
[11] M. Rafieian Esfahani, B. Yazdani, M. Barati, A. Naqsh, and N. Janatian, "Drivers, enablers, and challenges of sustainability in the pharmaceutical supply chain: A systematic review," Supply Chain Management, vol. 25, no. 78, pp. 89-108, 2023.
[12] M. R. Amin, N. Akhtar, M. E. Hoque, A. R. Nabil, and K. M. S. Hossain, "Blockchain-Enabled Traceability in Pharmaceutical Supply Chains: An Integrated Engineering and IT Management Framework for Regulatory Compliance and Pandemic Resilience," Journal of Computer Science and Technology Studies, vol. 7, no. 10, pp. 343–356, 2025, doi: 10.32996/jcsts.2025.7.10.37.
[13] Y. Wen, Y. Wei, and L. Liu, "Research on operation strategy of multiple channels pharmaceutical supply chain based on blockchain technology," Scientific Reports, vol. 15, p. 17033, 2025, doi: 10.1038/s41598-025-00727-7.
[14] D. A. Adeleke and A. D. Samuel, "The role of Blockchain technology in ensuring pharmaceutical supply chain integrity and traceability," Finance & Accounting, vol. 6, no. 11, pp. 2120–2133, 2024, doi: 10.51594/farj.v6i11.1700.
[15] C. Sim, H. Zhang, and M. L. Chang, "Improving End-to-End Traceability and Pharma Supply Chain Resilience using Blockchain," Blockchain in Healthcare Today, vol. 5, 2022, doi: 10.30953/bhty.v5.231.
[16] A. Nikzadipanah, M. Rahdar, and G. Bandani, "Resilience of the Drug Supply Chain Using Blockchain Technology," Journal of Military Medicine, vol. 26, no. 3, pp. 2332-2346, 2024, doi: 10.30491/JMM.2024.1006641.1154.
[17] I. Ioannou and G. Demirel, "Blockchain and supply chain finance: a critical literature review at the intersection of operations, finance and law," Journal of Banking and Financial Technology, vol. 6, no. 1, pp. 83–107, 2022.
[18] G. Tripathi, M. A. Ahad, and G. Casalino, "A comprehensive review of blockchain technology: Underlying principles and historical background with future challenges," Decision Analytics Journal, vol. 9, p. 100344, 2023, doi: 10.1016/j.dajour.2023.100344.
[19] M. A. Alqarni, M. S. Alkatheiri, S. H. Chauhdary, and S. Saleem, "Use of Blockchain-Based Smart Contracts in Logistics and Supply Chains," Electronics, vol. 12, no. 6, p. 1340, 2023.
[20] A. A. A. Sharabati and E. R. Jreisat, "Blockchain technology implementation in supply chain management: A literature review," Sustainability, vol. 16, no. 7, p. 2823, 2024.
[21] M. Uddin, "Blockchain Medledger: Hyperledger fabric enabled drug traceability system for counterfeit drugs in pharmaceutical industry," *International Journal of Pharmaceutics*, vol. 597, p. 120235, 2021. [Online]. Available: https://doi.org/10.1016/j.ijpharm.2021.120235
[22] G. K. Badhotiya, V. P. Sharma, S. Prakash, V. Kalluri, and R. Singh, "Investigation and assessment of blockchain technology adoption in the pharmaceutical supply chain," Materials Today: Proceedings, vol. 46, pp. 10776-10780, 2021. https://doi.org/10.1016/j.matpr.2021.01.673
[23] E. Fernando, Meyliana and Surjandy, "Success Factor of Implementation Blockchain Technology in Pharmaceutical Industry: A Literature Review," 2019 6th International Conference on Information Technology, Computer and Electrical Engineering (ICITACEE), Semarang, Indonesia, 2019, pp. 1-5, doi: 10.1109/ICITACEE.2019.8904335.
[24] M. Tangsakul and P. Sureeyatanapas, "Understanding critical barriers to the adoption of blockchain technology in the logistics context: An interpretive structural modelling approach," Journal of Open Innovation: Technology, Market, and Complexity, vol. 10, no. 3, p. 100355, 2024, doi: 10.1016/j.joitmc.2024.100355.
[25] C. Walsh, P. O’Reilly, R. Gleasure, J. McAvoy, and K. O’Leary, "Understanding manager resistance to blockchain systems," European Management Journal, vol. 39, no. 3, pp. 353–365, 2021, doi: 10.1016/j.emj.2020.10.001.
[26] A. K. Singh, V. P. Kumar, G. Dehdasht, S. R. Mohandes, P. Manu, and F. P. Rahimian, "Investigating the barriers to the adoption of blockchain technology in sustainable construction projects," Journal of Cleaner Production, vol. 403, p. 136840, 2023, doi: 10.1016/j.jclepro.2023.136840.
[27] A. K. Singh, V. R. P. Kumar, M. Irfan, S. R. Mohandes, and U. Awan, "Revealing the Barriers of Blockchain Technology for Supply Chain Transparency and Sustainability in the Construction Industry: An Application of Pythagorean FAHP Methods," Sustainability, vol. 15, no. 13, p. 10681, 2023, doi: 10.3390/su151310681.
[28] T. Riedel, "Addressing challenges: Adopting blockchain technology in the pharmaceutical industry for enhanced sustainability," Sustainability, vol. 16, no. 8, p. 3102, 2024, doi: 10.3390/su16083102.
[29] M. Peron, R. Pozzi, and M. P. Ciano, "Blockchain in the pharmaceutical sector: empirical evidence on the associated challenges and countermeasures," International Journal of Production Economics, vol. 288, p. 109685, 2025. https://doi.org/10.1016/j.ijpe.2025.109685
[30] F. Salzano, L. Marchesi, R. Pareschi, and R. Tonelli, "Integrating blockchain technology within an information ecosystem," Blockchain: Research and Applications, vol. 5, no. 4, p. 100225, 2024, doi: 10.1016/j.bcra.2024.100225.
[31] S. Joshi and M. Sharma, "Assessment of implementation barriers of blockchain technology in public healthcare: evidences from developing countries," Health Systems (Basingstoke, England), vol. 12, no. 2, pp. 223–242, 2023, doi: 10.1080/20476965.2023.2206446.
[32] J. Carlos Ferreira, L. B. Elvas, R. Correia, and M. Mascarenhas, "Enhancing EHR Interoperability and Security through Distributed Ledger Technology: A Review," Healthcare (Basel, Switzerland), vol. 12, no. 19, p. 1967, 2024, doi: 10.3390/healthcare12191967.
[33] T. Sivaram, "Recent developments and challenges using blockchain techniques for peer-to-peer energy trading: A review," Results in Engineering, p. 103666, 2024, doi: 10.1016/j.rineng.2024.103666.
[34] G. K. Badhotiya, V. P. Sharma, S. Prakash, V. Kalluri, and R. Singh, "Investigation and assessment of blockchain technology adoption in the pharmaceutical supply chain," Materials Today: Proceedings, vol. 46, pp. 10776-10780, 2021. https://doi.org/10.1016/j.matpr.2021.01.673
[35] M. Peron, R. Pozzi, and M. P. Ciano, "Blockchain in the pharmaceutical sector: empirical evidence on the associated challenges and countermeasures," International Journal of Production Economics, vol. 288, p. 109685, 2025. https://doi.org/10.1016/j.ijpe.2025.109685
[36] S. Cizmecioglu, A. Calik, and E. Boz, "Review of barriers to implement blockchain technologies in logistics," in Proc. 7th Int. Conf. Blockchain Technol. Appl. (ICBTA '24), 2025, pp. 72–76, doi: 10.1145/3708622.3708630.
[37] U. H. Govindarajan, G. Narang, D. K. Singh, and V. S. Yadav, "Blockchain technologies adoption in healthcare: Overcoming barriers amid the hype cycle to enhance patient care," Technological Forecasting and Social Change, vol. 213, p. 124031, 2025. https://doi.org/10.1016/j.techfore.2025.124031
[38] A. Punia, P. Gulia, N. S. Gill, E. Ibeke, C. Iwendi, and P. K. Shukla, "A systematic review on blockchain-based access control systems in cloud environment," Journal of Cloud Computing, vol. 13, no. 1, p. 146, 2024, doi: 10.1186/s13677-024-00697-7.
[39] A. Ghadge, M. Bourlakis, S. Kamble, and S. Seuring, "Blockchain implementation in pharmaceutical supply chains: A review and conceptual framework," International Journal of Production Research, vol. 61, no. 19, pp. 6633–6651, 2023. https://doi.org/10.1080/00207543.2022.2125595
[40] G. Tiwari, P. Channakkalavara, G. Singh, and P. N. K. Sarella, "Enhancing security, transparency, and efficiency of blockchain technology in pharmaceutical supply chain," Int. J. Pharm. Qual. Assur., vol. 15, no. 02, pp. 1009-1016, 2024.
[41] B. Anthony Jnr, "Enhancing blockchain interoperability and intraoperability capabilities in collaborative enterprise—a standardized architecture perspective," Enterprise Information Systems, vol. 18, no. 3, p. 2296647, 2024, doi: 10.1080/17517575.2023.2296647.
[42] S. Khan, A. Haleem, and M. I. Khan, "Risk management in Halal supply chain: An integrated fuzzy Delphi and DEMATEL approach," Journal of Modelling in Management, vol. 16, no. 1, pp. 172-214, 2021.
[43] C. H. Cheng and Y. Lin, "Evaluating the best main battle tank using fuzzy decision theory with linguistic criteria evaluation," European Journal of Operational Research, vol. 142, no. 1, pp.
[44] J. S. Horng, S. F. Chou, C. H. Liu, and C. Y. Tsai, "Creativity, aesthetics and eco-friendliness: A physical dining environment design synthetic assessment model of innovative restaurants," Tourism Management, vol. 36, pp. 15-25, 2013.
[45] P. T. Chang, L. C. Huang, and H. J. Lin, "The fuzzy Delphi method via fuzzy statistics and membership function setting and an application to the human resources," Fuzzy Sets and Systems, vol. 112, pp. 511-520, 2000. (In Persian).
[46] S. Abdallah and N. Nizamuddin, “Blockchain-based solution for pharma supply chain industry,” Computers & Industrial Engineering, vol. 177, p. 108997, 2023, doi: 10.1016/j.cie.2023.108997.
دوره 28، شماره 90 - شماره پیاپی 90
شماره پیا پی 90 بهار 1405
خرداد 1405
صفحه 1-20
  • تاریخ دریافت: 22 آبان 1404
  • تاریخ بازنگری: 29 آذر 1404
  • تاریخ پذیرش: 11 خرداد 1405
  • تاریخ انتشار: 25 خرداد 1405